Navigation Links
The Systemic Lupus Erythematosus Market Will Grow Dramatically Over the Next Decade, Increasing from Approximately $900 Million in 2012 to $4 Billion in 2022
Date:10/30/2013

BURLINGTON, Mass., Oct. 30, 2013 /PRNewswire/ --  Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the systemic lupus erythematosus (SLE) market will grow dramatically over the next decade from approximately $900 million in 2012 to $4 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Systemic Lupus Erythematosus finds that Benlysta, the first approved biologic for the disease, will be the primary driver of market growth throughout the forecast period with sales in 2022 of $1.1 billion. However, physician perceptions of Benlysta's modest efficacy, slow onset to action and restrictive label—which does not include patients with severe, active renal and central nervous system disease—leave opportunity for emerging agents with better efficacy profiles and acceptable safety to gain market share. In the B-cell modulator class alone, the anticipated entry of UCB's epratuzumab, Eli Lilly's tabalumab and Anthera Pharmaceuticals' blisibimod will drive sales of $1.1 billion by 2022, accounting for almost 30 percent of total SLE sales. Though concerns regarding safety will initially limit their uptake, as physicians gain experience towards the end of our forecast period, these new agents may see use ahead of Benlysta. As a class, the B-cell modulators will account for 65 percent of total market sales in 2022.

The report also finds that the uptake of Bristol-Myers Squibb's Orencia for the treatment of lupus nephritis, beginning in 2018, will be a significant driver of SLE market growth. Orencia's patient share in 2022 will be modest; however, the anticipated high price of the 30 mg/kg dose being tested in Phase III trials will drive its sales to account for approximately 19 percent of total SLE sales in 2022.

"Benlysta has received a lukewarm reception to the SLE market owing primarily to physician perceptions of its modest efficacy, slow onset to action and inability to be used in the high unmet need population of patients with severe, life-threatening organ involvement," said Decision Resources Analyst Laura Croal, Ph.D. "Owing to its high price in a largely generic market, Benlysta will lead market sales in 2022 on the strengths of its excellent safety profile, demonstrated efficacy in pivotal trials and first-to-market advantage. However, the drug will be vulnerable to emerging agents with acceptable safety profiles that demonstrate improvements in these key perceived weaknesses."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
2. Rheumatologists in the EU5 Give the Highest Satisfaction and Performance Ratings to Rituxan and Benlysta for the Treatment of Systemic Lupus Erythematosus (SLE)
3. Indias Largest Generic Drugmaker Ranbaxy Pays $500 Million to Settle Systemic Generic Drug Manufacturing Fraud
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. New Findings Offer Systemic Solutions to Address Non-communicable Diseases (NCDs) in Low- and Middle-income Countries
6. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
7. New Research Available on the Multi-Billion Dollar Transmucosal Drug Delivery and Systemic Nasal Sprays Markets
8. New ALR-LRI Collaboration to Accelerate New Treatments for Lupus
9. Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
10. Lupus Foundation of Florida Applauds Support for Biosimilars Legislation
11. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... 18 months after its February 2016 launch, market access ... of three new senior people to its rapidly expanding ... and James Wright bring decades of specialist ... Tammy Wynne joins as Director, Value Communication, ... over ten years, experience in global market access consultancy ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... 26, 2017 , ... Founded as an independent institute in 1968, The ... special education. In 2018, Glenholme will celebrate its first 50 years and set ... farm for Hackney show ponies, was generously donated by Jean White Van Sinderen to ...
(Date:9/26/2017)... , ... September 26, 2017 , ... ... are collaborating on strategic and tactical plans for Pittcon 2018. As of July ... as president along with his named vice president, Charles Gardner, (ChemImage Corporation) and ...
(Date:9/26/2017)... ... ... “Childhood Memories of a Virginia Wanderer”: an entertaining look inside the author’s ... youth. “Childhood Memories of a Virginia Wanderer” is the creation of published author, Dewey ... He received his BS from Idaho State University in Adult Education, as well as ...
(Date:9/26/2017)... ... September 26, 2017 , ... Time out for Daddy is ... boy's newfound understanding that even grownups make mistakes. “Time Out for Daddy” is the ... for her entire life and whose passion for children inspired her to write this ...
(Date:9/25/2017)... ... ... The Renal Support Network (RSN) is proud to announce the launch of our ... on RSN’s mission to empower people who have kidney disease to become knowledgeable about ... unique website is loaded with hundreds of exclusive personal stories. These posts are written ...
Breaking Medicine News(10 mins):